Precision therapeutics for inflammatory bowel disease using engineered probiotics: Strategies and optimization

Area of Science:

• Microbiology
• Gastroenterology
• Biotechnology

Background:

• Inflammatory bowel disease (IBD) incidence is rising globally.
• Gut microbiota dysbiosis is a key factor in IBD pathogenesis.
• Traditional probiotics show limitations in IBD treatment efficacy and variability.

Purpose of the Study:

• To review the advancements in engineered probiotics for IBD therapy.
• To explore strategies for enhancing probiotic efficacy and targeting in IBD.
• To highlight the potential of engineered probiotics in precision medicine for IBD.

Main Methods:

• Review of research on gene editing strategies for chassis strains.
• Analysis of bioengineering modifications for targeted IBD therapy.
• Examination of optimized delivery systems and AI-driven strain design.

Main Results:

• Engineered probiotics demonstrate enhanced microenvironment responsiveness and precise therapeutic targeting.
• These probiotics show significant effects in intestinal mucosal repair and immune modulation.
• AI-driven approaches are advancing strain screening and design for IBD.

Conclusions:

• Engineered probiotics represent a frontier in IBD treatment, offering improved precision, safety, and personalization.
• Genetic modification and synthetic biology enable targeted reactivity to the intestinal pathological microenvironment.
• Further research and clinical application of engineered probiotics hold potential for accelerating therapeutic innovation in IBD.